Open Access
Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials
Michael W. Weiner,Dallas P. Veitch,Paul S. Aisen,Laurel A. Beckett,Nigel J. Cairns,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,John C. Morris,Ronald C. Petersen,Andrew J. Saykin,Leslie M. Shaw,Arthur W. Toga,John Q. Trojanowski,Alzheimer’s Disease Neuroimaging Initiative +15 more
Reads0
Chats0
TLDR
The Alzheimer's Disease Neuroimaging Initiative (ADNI) has continued development and standardization of methodologies for biomarkers and has provided an increased depth and breadth of data available to qualified researchers.About:
The article was published on 2017-04-01 and is currently open access. It has received 169 citations till now. The article focuses on the topics: Alzheimer's Disease Neuroimaging Initiative & Biomarker (medicine).read more
Citations
More filters
Journal ArticleDOI
Automated classification of Alzheimer's disease and mild cognitive impairment using a single MRI and deep neural networks
Silvia Basaia,Federica Agosta,Luca Wagner,Elisa Canu,Giuseppe Magnani,Roberto Santangelo,Massimo Filippi +6 more
TL;DR: A deep learning algorithm is built and validated predicting the individual diagnosis of Alzheimer's disease and mild cognitive impairment who will convert to AD (c-MCI) based on a single cross-sectional brain structural MRI scan, demonstrating that it is exploitable by not-trained operators and likely to be generalizable to unseen patient data.
Journal ArticleDOI
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative
Dallas P. Veitch,Michael W. Weiner,Paul S. Aisen,Laurel A. Beckett,Nigel J. Cairns,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,John C. Morris,Ronald C. Petersen,Andrew J. Saykin,Leslie M. Shaw,Arthur W. Toga,John Q. Trojanowski +14 more
TL;DR: Select topics that provide insights into AD progression are discussed and how this knowledge may improve clinical trials are outlined.
Journal ArticleDOI
Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer’s Disease using structural MR and FDG-PET images
TL;DR: This paper proposes a novel deep-learning-based framework to discriminate individuals with AD utilizing a multimodal and multiscale deep neural network and delivers 82.4% accuracy and 94.23% sensitivity in classifying individuals with clinical diagnosis of probable AD.
Journal ArticleDOI
Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers.
Kwangsik Nho,Alexandra Kueider-Paisley,Siamak MahmoudianDehkordi,Matthias Arnold,Shannon L. Risacher,Gregory Louie,Colette Blach,Rebecca Baillie,Xianlin Han,Gabi Kastenmüller,Wei Jia,Guoxiang Xie,Shahzad Ahmad,Thomas Hankemeier,Cornelia M. van Duijn,John Q. Trojanowski,Leslie M. Shaw,Michael W. Weiner,P. Murali Doraiswamy,Andrew J. Saykin,Rima Kaddurah-Daouk +20 more
TL;DR: In this paper, the association of BAs with the "A/T/N" (amyloid, tau, and neurodegeneration) biomarkers for AD: cerebrospinal fluid (CSF), atrophy (magnetic resonance imaging), and brain glucose metabolism (FDG PET).
Journal ArticleDOI
Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology
Marc Suárez-Calvet,Marc Suárez-Calvet,Estrella Morenas-Rodríguez,Estrella Morenas-Rodríguez,Gernot Kleinberger,Kai Schlepckow,Miguel Ángel Araque Caballero,Nicolai Franzmeier,Anja Capell,Katrin Fellerer,Brigitte Nuscher,Erden Eren,Erden Eren,Johannes Levin,Johannes Levin,Yuetiva Deming,Laura Piccio,Celeste M. Karch,Carlos Cruchaga,Leslie M. Shaw,John Q. Trojanowski,Michael W. Weiner,Michael Ewers,Christian Haass,Christian Haass +24 more
TL;DR: CSF sTREM2 increased in early symptomatic stages of late-onset AD but, unexpectedly, was observed decreased at the earliest asymptomatic phase when only abnormal Aβ pathology but no tau pathology or neurodegeneration, is present.
References
More filters
Journal ArticleDOI
Hierarchical Interactions Model for Predicting Mild Cognitive Impairment (MCI) to Alzheimer's Disease (AD) Conversion
TL;DR: This paper proposes to fit the prediction models using pairwise biosignature interactions, thus capturing higher-order relationship among biosignatures, and discovers several significant interactions predictive of MCI-to-AD conversion.
Journal ArticleDOI
ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
Liana G. Apostolova,Kristy S. Hwang,Omid Kohannim,David Avila,David Elashoff,Clifford R. Jack,Leslie M. Shaw,John Q. Trojanowski,Michael W. Weiner,Paul M. Thompson +9 more
TL;DR: The proposed biomarker trajectory in AD, which postulates that amyloid markers become abnormal early in the disease course while markers of neurodegeneration become abnormal later in the Disease course, is supported and suggests that ApoE4 could be at least partially responsible for some of the observed disease heterogeneity.
Journal ArticleDOI
Ontology driven decision support for the diagnosis of mild cognitive impairment
TL;DR: An ontology driven decision support method which is an automated procedure for diagnosing MCI through magnetic resonance imaging (MRI) and construct a rule set using machine learning algorithms to automatically distinguish MCI patients from normal controls.
Journal ArticleDOI
Brain structure and function as mediators of the effects of amyloid on memory
Niklas Mattsson,Philip S. Insel,Paul S. Aisen,William J. Jagust,Scott Mackin,Michael W. Weiner +5 more
TL;DR: Testing whether effects of β-amyloid pathology on episodic memory were mediated by metabolism and gray matter volume in the early stages of Alzheimer disease found changes in brain structure and function appear to be, in part, downstream events from Aβ pathology, ultimately resulting in episodicMemory deficits.
Journal ArticleDOI
White matter signal abnormality quality differentiates mild cognitive impairment that converts to Alzheimer's disease from nonconverters.
Emily R. Lindemer,Emily R. Lindemer,David H. Salat,David H. Salat,Eric E. Smith,Khoa Nguyen,Bruce Fischl,Douglas N. Greve +7 more
TL;DR: Data demonstrate changes in white matter tissue properties that occur within WMSA in individuals with MCI that will subsequently obtain a clinical diagnosis of AD within 18 months and suggest that WMSAs are a critical component for this conversion and are acritical component of this clinical syndrome.
Related Papers (5)
2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Michael W. Weiner,Dallas P. Veitch,Paul S. Aisen,Laurel A. Beckett,Nigel J. Cairns,Jesse M. Cedarbaum,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,Johan Luthman,John C. Morris,Ronald C. Petersen,Andrew J. Saykin,Leslie M. Shaw,Li Shen,Adam J. Schwarz,Arthur W. Toga,John Q. Trojanowski,Alzheimer’s Disease Neuroimaging Initiative +19 more
Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease.
Dallas P. Veitch,Michael W. Weiner,Paul S. Aisen,Laurel A. Beckett,Charles DeCarli,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,Susan M. Landau,John C. Morris,Ozioma C. Okonkwo,Richard J. Perrin,Ronald C. Petersen,Monica Rivera-Mindt,Andrew J. Saykin,Leslie M. Shaw,Arthur W. Toga,Duygu Tosun,John Q. Trojanowski,Alzheimer’s Disease Neuroimaging Initiative +20 more